glp-1 agonists weight loss side effects For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Glucagon-like Receptor-1 agonists for obesity:
Description
Dominant Region : North America remains the leading region owing to advanced healthcare systems, high diagnosis rates, and strong reimbursement for diabetes and obesity drugs
Huang, G., Zhang, Y., Zhang, Y
The cornerstone of MASLD treatment has been lifestyle interventions, focusing on a healthful diet and regular physical activity
For many patients, bariatric surgery remains the most effective and durable treatment available
A newer finding from Phase 3 data is dysesthesia (skin tingling or sensitivity) affecting about 21% of participants at the highest dose
Ku SC, Chang HC
